10Aug 2017

IMMUNOHISTOCHEMICAL ESTIMATION OF FOXP3 EXPRESSION IN T-REG AND CANCER CELLS IN IRAQI LUNG CANCER TISSUE.

  • Department of clinical laboratory sciences, Pharmacy college Al-Mustansiriyah University, Baghdad, Iraq.
  • Consultant Thoracic and vascular surgeon, Bagdad University, Baghdad, Iraq.
  • Consultant chest physician, Bagdad University, Baghdad, Iraq.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Lung cancer is the most common cancer worldwide accounting for 1.61 million new cases annually and it is the most common reason of death from cancer in different regions. FOXP3 is immune marker known to be expression in T-regulatory cells. Recently, it has been confirmed that the tumor cells themselves can express FOXP3 leading to the tumor development and metastasis. Studies combining FOXP3 and lung cancer worldwide are very few. None of them was conducted in Iraq, therefore we aimed to this study. Formalin fixed paraffin embedded tissue blocks were selected for Immunohistochemistry study. streptavidin-biotinimmunoenzymatic antigen detection system was used. The number and intensity of FOXP3+ cells present within tumor-cell nuclei ,cytoplasm and T-reg infiltrating cells were counted and scored. Twenty two cases (73.3%) of lung cancer showed positive IHC expression of FOXP3 in the lymphocytic infiltrate, 21(70%) cases of lung cancer revealed positive nuclear expression in the tumor cells compared to only 3(13.63%) cases of benign lesions and 23 (76.7%) cases of lung cancer revealed positive cytoplasm expression .There is a high significant difference was noted between malignant and benign groups regarding the nuclear expression of FOXP3 p<0.001, as well as between cytoplasm expression. The highest score to be detected in nuclear expression of FOXP3 was score 3 in11 (36.67%) with high intensity 16 (53.3%) in malignant cases. While highest frequency of cases was noticed in score 1 of FOXP3 positive infiltrating lymphocytes 14(46.67%) in malignant cases with high intensity 18(60%). The present study results suggest that FOXP3 is useful immune markers with potential applications as prognostic markers in lung cancer.

  1. Elsayed, I. S.; Jazieh, A-R. and Moore,M.A.(2011). Lung Cancer Incidence in the Arab League Countries: Risk Factors and Control. Asian Pacific J. Cancer Prev. 12: 17-34.
  2. Ferlay, J.; Shin, H.R.; Bray, F.; Forman , D.; Mathers , C. and Parkin , D. M.(2010) . GLOBOCAN 2008 , Cancer Incidence and Mortality Worldwide: IARC Cancer Base. Lyon, France: International Agency for Research on Cancer.
  3. Iraqi Cancer Registry Center Publications (2009). Ministry of Health, Iraqi Cancer Board/ Baghdad.
  4. Travis, W.D.; Brambilla, E. and Riely, G.J.(2013). New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. J. Clin. Oncol. 31 (8):992-10.
  5. Woo, E.Y.; Chu, C.S.; Goletz, T.J.; et al.(2001). Regulatory CD4 CD25 T cells in tumors from patients with early-stage non-small. cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:4766?72.
  6. Woo, E.Y.; Yeh, H., Chu, C.S.and et al.(2002). Cutting edge: regulatory Tcells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168:4272?4276.
  7. Petersen, R. P.; Campa, M. J.; perlazza, J. S.; Onlon, D.; Joshi, M-B.; David H. HarpoleJr, D. H. and PatzJr, E. F.(2006). Tumor Infiltrating FOXP31 Regulatory T-cells Are Associated With Recurrence in Pathologic Stage I NSCLC Patients. CANCER, 107 (12):2866-72.
  8. Wieczorek, G.; Asemissen, A.; Mode, F.; Turbachova, I.; Floess, S. Liebenberg, V.; Baron, U.; Stauch, D.; Kotsch, K.; Pratschke, J.; Hamann, A.; Loddenkemper, C.; Stein, H.; Volk, H.D.; Hoffm?ller, U.; Gr?tzkau, A.; Mustea, A.; Huehn, J.; Scheibenbogen, C. and Olek, S. (2009).Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res., 69(2):599?608.
  9. Baratelli, F.; Lee, J. M.; Hazra, S.; Lin, Y.; Walser, T. C. and et al. (2010). PGE2 contributes to TGF-β induced T regulatory cell function in human non-small cell lung cancer. J. Transl. Res. 2(4):356-367.
  10. Hiraoka, N.; Onozato, K.; Kosuge, T.andHirohashi, S.(2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12:5423-34.
  11. Vigor?, L.; Rovelli, F., Massimo Colciago, M.; Giovanna D‟Amico, G.; Di Fede, G. and Lissoni, P.(2008). A clinical study of T-regulatory lymphocyte function in cancer patients in relation to tumor histotype disease extention, lymphocyte subtypes and cortisol secretion Research Article. Cancer Therapy, (6): 699-706.
  12. Lu, H.(2009). FOXP3 Expression and Prognosis: Role of Both the Tumor and T Cells. J. Clin. Oncol. 27 (11):1735-1736.
  13. Hinz, S.; Pagerols-Raluy, L.; Oberg,H-H.; Ammerpohl, O.; Gru?ssel, S.; Sipos, B.; Gru?tzmann, R.; Christian Pilarsky,C.; HendrikUngefroren, H.; Saeger,H-D.; Klo?ppel, G.; Kabelitz, D.; and KalthoffF,H. (2007).Foxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer. Cancer Res. 67 (17): 8344-50.
  14. Merlo, A.; Casalini ,P.; Carcangiu, M.L.; Malventano, C.; Triulzi, T.; M?nard, S.; et al.(2009).FOXP3 expression and overall survival in breast cancer. J. Clin. Oncol. 27:1746-52.
  15. Ziegler, S.F. (2006). FOXP3 of mice and men. Annu. Rev. Immunol. 24:209-26.
  16. Zou, W. (2006).Regulatory T cells, tumour immunity and immune- therapy. Nat. Rev. Immunol. 6:295-307.
  17. Dieckmann, D.; Plottner, H. (2001) .Ex vivo isolation and characteri- ization of CD4+CD25+ T cells with regulatory properties from human blood. J. Exp. Med. 193:1303-10.
  18. Khong, H. T. and Restifo, N. P. (2002).Natural selection of tumour variants in the generation of ?tumour escape‟ phenotypes. Nature Immunol . 3: 999?1005.
  19. Curiel, T. J.and et al. (2004).Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and pre Khong, H. T. and Restifo, N. P. (2002). Natural selection of tumour variants in the generation of ?tumour escape‟ phenotypes. Nature Immunol. 3:999?1005.
  20. Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4 regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 6(4): 345?352.
  21. Ebert, L.M.; Tan, B.S.; Browning, J.; Svobodova, S.; Russell, S.E.; Kirkpatrick, N.; Gedye, C.; Moss, D.; Ping-Ng, S.; MacGregor, D.; Ian, I. D.; Cebon, J.; and Weisan Chen, W.(2008). The Regulatory T Cell?Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. Can.Res. 68(8):3001-9.
  22. Karanikas, V.; Speletas, M.; Zamanakou, M.; Kalala, F.; Loules, G.; Kerenidi, T.; Barda, A.K.; Gourgoulianis, K.I. and Germenis, A.E. (2008).Foxp3 expression in human cancer cells. J. Transl .Med . 6:19-27.
  23. Takenaka, M.; Seki, N.; toh, U.; Hattori, S.; Kawahara, A.; Yamaguchi,T.; Koura, K.; Takahashi, R.; Otsuka, H.; Takahashi,H.; Aiwakuma, N.; Nakagawa, S.; Fujii, T.; Sasada, T.; Yamaguchi, R.; Yano, H.; Shirouzu,K. And Kage,M.(2013). FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Molecular and clinical oncology, 1: 625-632.
  24. Zhang, H.Y. and Sun, H. (2010). Up-regulation of FOXP3 inhibits cell proliferation,migration and invasion in epithelial ovarian cancer. Cancer Letter, 287(1): 91-97.
  25. Lucas, S.; van Baren, N.; de Smet, C. and Coulie, P. G. (2012). Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples, Int. J. Cancer. 130: 1960?66.
  26. Shigematsu, Y; Hanagiri, T.; Shiota, H.; Kuroda, K.; Baba,T.; Ichiki, Y.; Yasuda,M.;Uramoto,H.;Takenoyama,M.;Yasumoto,K.;and Tanaka ,F.(2012). Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor‑specific cytotoxic T lymphocytes. Oncology Letters, 4: 625-630.
  27. Kim, M.; Grimmig, T.; Grimm, M.; Maria Lazariotou,M.; Meier, E.; Andreas Rosenwald, A.; Tsaur, I.; Blaheta, R.; Heemann, U.; Germer, C-T.; Waaga-Gasser, A. M.; and Gasser, M. (2013). Expression of Foxp3 in Colorectal Cancer but Not in Treg Cells Correlates with Disease Progression in Patients with Colorectal Cancer. PLoS ONE 8(1): e53630.
  28. Xia, M.; Zhao, M-q.; Wu, K.; Lin,X-y.; Liu,Y. and Ye-jun Qin, Y-j.(2013). Investigations on the clinical significance of FOXP3 protein expression in cervical oesophageal cancer and the number of FOXP3 tumour infiltrating lymphocytes. Journal of International Medical Research , 41(4) :1002?1008.
  29. Hu, J-L.; Yang, Z.; Tang, J-R.; Fu,X-Q.; Yao, L-J.(2013).Effects of Gastric Cancer Cells on the Differentiation of Treg Cells. Asian Pac. J. Cancer Prev. 14 (8): 4607-10.
  30. Um, S-W.; Lee, S.H.; Kim,H.; Kwon, J.; Kim, H.; Kang, J.S. and Lee, W.J.(2011). The Regulation of FOXP3 Expression by the treatment of TGF-β and the Modification of DNA Methylation in Lung Cancer Cell Lines Tuberculosis and Respiratory Diseases, 70(3):206-17.
  31. Milne, K.; Ko? bel, M.; Kalloger, S.E.; Barnes, R.O.; Gao, D. and et al. (2009). Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors .PLoSONE ,4(7): e6412.
  32. Finn , O.J. (2008).Molecular Origins of Cancer Cancer Immunology. N. Engl. J .Med. 358:2704-15.
  33. Feng, J.; Zhang, X.; Zhu, H.; Wang, X.; Ni, S.and Huang, J. (2012).High Expression of FoxP1 Is Associated With Improved Survival in Patients With Non?Small Cell Lung Cancer. J. Clin. Pathol. 138:230-235.
  34. Dimitrakopoulos, F-I.d.; papadaki, h.; Antonacopoulou, A.G.; Kottorou, A.; Gotsis, A.D.; Scopa, C.; Kalofonos, H.P.; and Mouzaki, A.(2011). Association of FOXP3 Expression with Non-small Cell Lung Cancer. Anticancer Research, 31 (5): 1677-1683.
  35. Salama ,P.;Phillips , M.; Grieu, F.; Morris, M.; Zeps, N. and et al. (2008) Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer. J. Clin. Oncol. 27: 186?192
  36. Zuo, T.; Liu, R.; Zhang, H.; Chang, X.; Liu, Y.; Wang, L.; heng, P. and Liu, Y.(2007a.). FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest . 117(12):3765-73.
  37. Tao, H.; Mimura, Y.; Aoe, K.; Kobayashi, S.; Yamamoto, H.; Matsuda, E.; Okabe, K.; Matsumoto, T.; Sugi, K. and Ueoka, H. (2012). Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer, 75(1): 95-101.
  38. Kinoshita, T.; Ishii, G.; Hiraoka, N.; Hirayama,S.; Yamauchi, C. et al. (2013).Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with apoor outcome in lung adenocarcinoma .Cancer Sci . 104( 4 ): 409?415.

[Suhad Faisal Hatem Al-Mugdadi, Waleed M.Hussen and Mustafa N. A. Ali. (2017); IMMUNOHISTOCHEMICAL ESTIMATION OF FOXP3 EXPRESSION IN T-REG AND CANCER CELLS IN IRAQI LUNG CANCER TISSUE. Int. J. of Adv. Res. 5 (Aug). 87-95] (ISSN 2320-5407). www.journalijar.com

Dr.Suhad faisal hatem

DOI:

Article DOI: 10.21474/IJAR01/5037      
DOI URL: https://dx.doi.org/10.21474/IJAR01/5037

Download Full Paper

Download PDF No. of Downloads: 22 | No. of Views: 84